What are the latest advances in Megalencephaly Capillary Malformation Polymicrogyria Syndrome (mcap)?

Megalencephaly Capillary Malformation Polymicrogyria Syndrome (MCAP) is a complex overgrowth disorder primarily caused by somatic mutations in the PIK3CA gene. Current research is shifting toward precision medicine, specifically targeting the PI3K/AKT/mTOR signaling pathway with targeted inhibitors to manage the clinical manifestations of this rare condition.

What are the primary research directions for MCAP?

The most promising research for Megalencephaly Capillary Malformation Polymicrogyria Syndrome (MCAP) involves the investigation of PI3K inhibitors. Because MCAP is driven by PIK3CA-related overgrowth, researchers are studying how pharmacological inhibition of this pathway can potentially slow or stabilize the tissue overgrowth and vascular malformations characteristic of the syndrome. These studies are currently focused on safety and dosage optimization rather than a curative approach.

What recent scientific breakthroughs have been made?

Recent literature highlights the identification of specific somatic mosaic mutations, which has fundamentally changed how clinicians approach the diagnosis of Megalencephaly Capillary Malformation Polymicrogyria Syndrome (MCAP). Key findings include:

• Targeted Therapy: Early-phase clinical trials are testing PI3K inhibitors (such as alpelisib) to mitigate severe overgrowth in patients with PIK3CA-related conditions.


• Genetic Mapping: Improved next-generation sequencing (NGS) of affected tissue samples—rather than just blood samples—has significantly increased the sensitivity of diagnosing MCAP.


• Clinical Registries: Global consortia are standardizing longitudinal data collection to better understand the natural history of Megalencephaly Capillary Malformation Polymicrogyria Syndrome (MCAP).

How can patients participate in research?

Participation in research is vital for the 23 community members currently sharing their experiences on DiseaseMaps.org and others worldwide. Families should monitor ClinicalTrials.gov by searching for "PIK3CA" or "MCAP" to identify active studies. It is essential to work closely with a geneticist or a pediatric neurologist who specializes in overgrowth syndromes to determine if a specific trial is appropriate for a patient’s unique clinical profile.

Next steps

• Consult a multidisciplinary team, including a geneticist and a pediatric neurologist, to discuss the latest clinical trial eligibility.


• Register with the NIH GARD patient registry or disease-specific foundations to stay informed about recruitment opportunities.


• Join the community at DiseaseMaps.org to connect with others affected by Megalencephaly Capillary Malformation Polymicrogyria Syndrome (MCAP).

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): MCAP Syndrome


• Orphanet: Megalencephaly-capillary malformation-polymicrogyria syndrome


• OMIM (Online Mendelian Inheritance in Man): #603387


• The PIK3CA-Related Overgrowth Spectrum (PROS) clinical research literature via PubMed